Sanofi Market Cap 2011-2025 | SNY
Sanofi market cap history and chart from 2011 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Sanofi market cap as of November 18, 2025 is $127.15B.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $127.146B | $44.458B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $965.899B | 46.46 |
| Johnson & Johnson (JNJ) | United States | $480.847B | 19.23 |
| AbbVie (ABBV) | United States | $413.568B | 24.76 |
| Roche Holding AG (RHHBY) | Switzerland | $283.672B | 0.00 |
| Novartis AG (NVS) | Switzerland | $277.889B | 14.73 |
| Merck (MRK) | United States | $230.481B | 10.73 |
| Novo Nordisk (NVO) | Denmark | $216.374B | 12.69 |
| Pfizer (PFE) | United States | $142.598B | 7.84 |
| Bayer (BAYRY) | Germany | $31.477B | 5.52 |
| Innoviva (INVA) | United States | $1.643B | 8.23 |